Related Experiment Video
Updated: Nov 21, 2025
Mouse Models for Graft Arteriosclerosis
Published on: May 14, 2013
Guidelines for mono, double and triple antithrombotic therapy
Renate C A E van Uden1,2, Ilse Houtenbos3, Anita Griffioen-Keijzer3
1Hospital Pharmacy, Spaarne Gasthuis, Haarlem, Noord-Holland, Netherlands.
Insights
Managing antithrombotic therapy requires careful consideration of multiple indications. This overview simplifies complex guidelines, advising against lifelong dual or triple therapy for patients needing antithrombotic treatment.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Antithrombotic therapy guidelines are complex, particularly for patients with multiple indications.
- Lifelong dual or triple antithrombotic therapy is generally not recommended.
Purpose of the Study:
- To provide an overview of antithrombotic therapy guidelines.
- To outline common indications for mono, double, and triple antithrombotic therapy.
- To specify preferred therapies and recommended durations.
Main Methods:
- Review of European and Dutch guidelines for antithrombotic therapy.
- Inclusion of antiplatelet agents and therapeutic anticoagulation (vitamin K antagonists, direct oral anticoagulants).
Main Results:
- Detailed indications for various antithrombotic regimens (mono, double, triple therapy).
- Recommendations on preferred antithrombotic agents and treatment durations.
- Emphasis on avoiding prolonged dual or triple antithrombotic therapy.
Conclusions:
- Simplifies complex antithrombotic therapy decision-making.
- Provides clear guidance on appropriate use and duration of antiplatelet and anticoagulant therapies.
- Aims to improve patient outcomes by optimizing antithrombotic treatment strategies.
Abstract:
Guidelines for antithrombotic therapy are complex, especially if a patient has several indications that require antithrombotic therapy. In general, no patient should receive lifelong double or triple antithrombotic therapy. In this overview, we outline the most common indications for mono, double and triple antithrombotic therapy; the preferred antithrombotic therapy and the recommended duration of therapy. Both antiplatelet therapy and therapeutic anticoagulation therapy with vitamin K antagonists or direct oral anticoagulants were included. European guidelines were used or, if no European guidelines were available, the Dutch guidelines were used.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Atherosclerosis III: Management
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care